Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use

Applied Radiation and Isotopes

Volumn 65, Issue 12, 2007, Pages 1359-1362

  Scott, Peter J H ^a   Kilbourn, Michael R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

18F Labeled pet tracers; Kryptofix 2.2.2; Quality control; Thin layer chromatography

Indexed keywords

FALSE NEGATIVE RESULTS; HEXACOSANES; RADIOPHARMACEUTICALS; RESIDUAL KRYPTOFIX;

NITROGEN COMPOUNDS; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; STABILIZERS (AGENTS); THIN LAYER CHROMATOGRAPHY;

RADIOACTIVE ELEMENTS;

1 (5 FLUORO 5 DEOXY ALPHA DEXTRO ARABINOFURANOSYL) 2 NITROIMIDAZOLE F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; CHEMICAL AGENT; CRYPTAND 2.2.2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL ANALYSIS; DRUG FORMULATION; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

BICYCLO COMPOUNDS, HETEROCYCLIC; CHROMATOGRAPHY, THIN LAYER; FLUORINE RADIOISOTOPES; HUMANS; INDICATORS AND REAGENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 35648998462     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2007.04.020     Document Type: Article

References (18)

1. 18FDG by cation exchange. Appl. Radiat. Isot. (Int. J. Radiat. Appl. Instrum. Part A) 42 (1991) 1189-1193
2. 18F]2-fluoro-2-deoxy-d-glucose. Nucl. Med. Biol. (Int. J. Radiat. Appl. Instrum. Part. B) 16 (1989) 385-387
3. Chen, J., Linder, K.E., Marinelli, E.R., Metcalfe, E., Nunn, A., Swenson, R.E., Tweedle, M., 2005. Stable radiopharmaceutical compositions and methods for their preparations. PCT Int. Appl. WO2004US23930, 117pp.
4. 18F]fluoro-2-deoxy-d-glucose. Appl. Radiat. Isot. 38 (1987) 605-610
5. Elmore A.R. Final report on the safety assessment of l-ascorbic acid, calcium ascorbate, magnesium ascorbate, magnesium ascorbyl phosphate, sodium ascorbate, and sodium ascorbyl phosphate as used in cosmetics. Int. J. Toxicol. 24 Suppl. 2 (2005) 51-111
6. 18F]FDG by gas chromatography using a nitrogen-selective detector. Nucl. Med. Biol. 20 (1993) 367-369
7. Kumar P., Wiebe L.I., Asikoglu M., Tandon M., and McEwan A.J.B. Microwave-assisted (radio)halogenation of nitroimidazole-based hypoxia markers. Appl. Radiat. Isot. 57 (2002) 697-703
8. In: Lewis Sr. R.J., and Tatken R.L. (Eds). Registry of Toxic Effects of Chemical Substances (1979), US Department of Health and Human Services, Center for Disease Control, Cincinnati, OH
9. 18F]FDG and other radiopharmaceuticals by LC/MS/MS. Nucl. Med. Biol. 29 (2002) 125-129
10. 18F]FDG preparations. Nucl. Med. Biol. 24 (1997) 193-195
11. Piert M., Machulla H.J., Picchio M., Reischl G., Ziegler S., Kumar P., Wester H.J., Beck R., McEwan A.J.B., Wiebe L.I., and Schwaiger M. J. Nucl. Med. 46 (2005) 106-113
12. 18F]-FAZA: reaction parameters and automation. Appl. Radiat. Isot. 62 (2005) 897-901
13. 18F]FLT) and simple method for metabolite analysis in plasma. Radiochim. Acta 94 (2006) 447-451
14. 18F-FLT and thymidine analogs: promise and pitfalls. J. Nucl. Med. 44 (2003) 1432-1434
15. 18F]-FLT and positron emission tomography. Nat. Med. 4 (1998) 1334-1336
16. USP-29, NF-24, 2006. Fludeoxyglucose F 18 Injection. USP-29, NF-24, Official Monographs. pp. 933-934.
17. 18F]-FDG PET in esophageal cancer. J. Nucl. Med. 46 (2005) 400-404
18. In: Zweig G., and Sherma J. (Eds). CRC Handbook of Chromatography vol. II (1972) 113